^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersCOMPANY:Bayer
i
Other names: Noria Therapeutics | PSMA Therapeutics | Bayer | @BayerPharma | KaNDY Therapeutics | Algeta | Medrad | Jenapharm | Dihon Pharmaceutical | Synpromics | NanoCor Therapeutics | Schering AG | Berlex Laboratories | Conceptus | Conceptus, | Intendis GmbH | Possis Medical | Zeptosens
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Evidence
News
3ms
Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01- HCRN GI23-643. (ASCO-GI 2026)
P2 | "Clinical Trial Registration Number: NCT06006923 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."
Clinical
|
MSI (Microsatellite instability)
|
Keytruda (pembrolizumab) • Stivarga (regorafenib)
4ms
Reframing Heart Failure Care: Amplifying Patient Voices in the Evolving Treatment Landscape. Provided by MedscapeLIVE. This activity is supported by an educational grant from Bayer. (AHA 2025)
"Provided by MedscapeLIVE. This activity is supported by an educational grant from Bayer."
Clinical • Grant
4ms
TRIPLE-SWITCH(SWOG/CCTG-PR26): Randomized Phase III Clinical Trial of Docetaxel with Androgen Receptor Pathway Inhibitors for Metastatic Castration-Sensitive Prostate Cancer Patients with a Suboptimal PSA Response (PCF 2025)
P3 | "Participants are randomized to one of two arms: ▪ Arm 1: Patients will continue on standard ADT + ARPI (abiraterone acetate with prednisone, apalutamide, enzalutamide, or darolutamide). SPL: Aura Bioscience, FKD, JBL (SWOG), Genentech (SWOG), Merck (Alliance), QED Therapeutics, Surge Therapeutics, Vaxiion, Viventia. Consultant/Advisory Board:Aura Bioscience, BMS, C2iGenomics, Ferring, Immunity Bio, Incyte, Gilead, Pfizer/EMD Serono, Protara, Surge Therapeutics, Tyra Biosciences, UroGen, Vaxiion, Verity; Patent – TCGA classifier; Honoraria – Grand Rounds Urology, UroToday"
Clinical • P3 data
|
docetaxel • Xtandi (enzalutamide) • abiraterone acetate • Nubeqa (darolutamide) • apalutamide
6ms
Nonacus, the University of Birmingham and Cancer Research UK invest £5m in bladder cancer trials (Nonacus Press Release)
"Nonacus, has invested in two West Midlands-based trials of an at-home urine test to prove its effectiveness in detecting bladder cancer, which affects more than 100,000 people in the UK...The trials use the Galeas Bladder genetic test, which a previous study—funded by Cancer Research UK and the Medical Research Council—found to accurately and consistently detect bladder cancer from a urine sample. "
Clinical data
|
GALEAS® Bladder
Share
